Cerenome CFO acquires 2,985 shares as grants vest

Q: How many CNSY shares did the CFO acquire from RSU vesting?

Andrew John Hugh MacIntyre Sims acquired 2,985 common shares from RSU vesting on October 1, 2026, in tranches of 1,533, 1,165 and 287 shares. No Rule 10b5-1 plan is reported.

Q: When did the CNSY CFO's RSU vesting schedules begin?

The three grants began vesting on October 1, 2025, April 1, 2026, and July 1, 2026, respectively. Each grant vests in twelve substantially equal quarterly installments.

The three grants began their substantially equal quarterly vesting schedules on three different dates, spanning October 2025 through July 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Cerenome, Inc. Chief Financial Officer Andrew John Hugh MacIntyre Sims reported three restricted stock unit grants vesting on October 1, 2026, and acquisition of 2,985 common shares. The three tranches were 1,533, 1,165 and 287 shares. Each Restricted Stock Unit represents a contingent right to receive one common share. No Rule 10b5-1 plan is reported.

Insider Trade Summary

2,985 shares exercised/converted

Exercise 6 txns

Insider Sims Andrew John Hugh MacIntyre

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units ^F2	1,533	$0.00	$0.00
Exercise	Restricted Stock Units ^F3	1,165	$0.00	$0.00
Exercise	Restricted Stock Units ^F4	287	$0.00	$0.00
Exercise	Common Stock ^{F2, F1}	1,533	$0.00	$0.00
Exercise	Common Stock ^{F3, F1}	1,165	$0.00	$0.00
Exercise	Common Stock ^{F4, F1}	287	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 24,085 contracts (Direct); Common Stock — 12,926 shares (Direct)

Footnotes (4)

F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.
F2. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on October 1, 2025.
F3. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on April 1, 2026.
F4. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on July 1, 2026.

Key Figures

Common shares acquired from RSU vesting: 2,985 shares First RSU grant tranche: 1,533 shares Second RSU grant tranche: 1,165 shares +2 more

5 metrics

Common shares acquired from RSU vesting 2,985 shares October 1, 2026

First RSU grant tranche 1,533 shares Vested October 1, 2026

Second RSU grant tranche 1,165 shares Vested October 1, 2026

Third RSU grant tranche 287 shares Vested October 1, 2026

Installments per RSU grant 12 substantially equal quarterly installments Each grant's vesting schedule

Key Terms

Restricted Stock Unit, contingent right, substantially equal quarterly installments

3 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents a contingent right"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right technical

"represents a contingent right to receive one share"

substantially equal quarterly installments financial

"occurs in twelve substantially equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CNSY shares did the CFO acquire from RSU vesting?

Andrew John Hugh MacIntyre Sims acquired 2,985 common shares from RSU vesting on October 1, 2026, in tranches of 1,533, 1,165 and 287 shares. No Rule 10b5-1 plan is reported.

When did the CNSY CFO's RSU vesting schedules begin?

The three grants began vesting on October 1, 2025, April 1, 2026, and July 1, 2026, respectively. Each grant vests in twelve substantially equal quarterly installments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/01/2026 - 08:00 AM Accepted by SEC EDGAR 10/01/2026 - 08:00 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sims Andrew John Hugh MacIntyre

(Last)

(First)

(Middle)

C/O PLUS THERAPEUTICS INC.

6420 LEVIT GREEN BOULEVARD, SUITE 310

(Street)

HOUSTON

TEXAS

77021

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CERENOME, INC. [ CNSY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2026		M		1,533⁽²⁾	A	$0⁽¹⁾	11,474	D
Common Stock	10/01/2026		M		1,165⁽³⁾	A	$0⁽¹⁾	12,639	D
Common Stock	10/01/2026		M		287⁽⁴⁾	A	$0⁽¹⁾	12,926	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	10/01/2026		M			1,533	⁽²⁾	⁽²⁾	Common Stock	1,533	$0	25,537	D
Restricted Stock Units	$0	10/01/2026		M			1,165	⁽³⁾	⁽³⁾	Common Stock	1,165	$0	24,372	D
Restricted Stock Units	$0	10/01/2026		M			287	⁽⁴⁾	⁽⁴⁾	Common Stock	287	$0	24,085	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.

2. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on October 1, 2025.

3. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on April 1, 2026.

4. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on July 1, 2026.

	/s/ Andrew Sims	10/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR